Beranda › Limfoma Burkitt
Uji klinis Limfoma Burkitt yang merekrut di AS
63 studi untuk Limfoma Burkitt merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Houston, TX21 studi
- Milwaukee, WI16 studi
- Philadelphia, PA16 studi
- New York City, NY14 studi
- Chicago, IL14 studi
- Cincinnati, OH12 studi
- Atlanta, GA12 studi
- Seattle, WA11 studi
- Durham, NC10 studi
- Boston, MA10 studi
- Kansas City, MO10 studi
- Los Angeles, CA10 studi
- Aurora, CO10 studi
- Washington, DC9 studi
- Orange, CA9 studi
- Minneapolis, MN9 studi
- Baldwin Park, CA9 studi
- Portland, OR8 studi
- Columbus, OH8 studi
- Buffalo, NY8 studi
- Baltimore, MD8 studi
- Ann Arbor, MI8 studi
- Nashville, TN8 studi
- San Francisco, CA8 studi
- Tampa, FL7 studi
- Clifton, NJ7 studi
- Dallas, TX7 studi
- Providence, RI7 studi
- Salt Lake City, UT7 studi
- Greenburgh, NY7 studi
- Richmond, VA7 studi
- Grand Rapids, MI7 studi
- San Antonio, TX7 studi
- Cleveland, OH7 studi
- Oklahoma City, OK7 studi
- Birmingham, AL7 studi
- Jacksonville, FL7 studi
- The Bronx, NY6 studi
- Mountain View, CA6 studi
- Cicero, IL6 studi
Berdasarkan negara bagian
- Alabama7 studi
- Arizona7 studi
- Arkansas5 studi
- California20 studi
- Colorado13 studi
- Connecticut7 studi
- Delaware7 studi
- Distrik Columbia5 studi
- Florida15 studi
- Georgia12 studi
- Hawaii5 studi
- Idaho6 studi
- Illinois14 studi
- Indiana6 studi
- Iowa7 studi
- Kansas6 studi
- Kentucky5 studi
- Louisiana4 studi
- Maine4 studi
- Maryland11 studi
- Massachusetts10 studi
- Michigan10 studi
- Minnesota10 studi
- Mississippi4 studi
- Missouri8 studi
- Nebraska5 studi
- Nevada6 studi
- New Hampshire4 studi
- New Jersey8 studi
- New Mexico3 studi
- New York20 studi
- North Carolina13 studi
- North Dakota5 studi
- Ohio17 studi
- Oklahoma7 studi
- Oregon8 studi
- Pennsylvania18 studi
- Rhode Island7 studi
- South Carolina5 studi
- South Dakota5 studi
- Tennessee10 studi
- Texas24 studi
- Utah7 studi
- Vermont3 studi
- Virginia7 studi
- Washington11 studi
- West Virginia3 studi
- Wisconsin17 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Menerima pesertaFase 2
366 Days – 46 Years · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Menerima pesertaFase 3
Usia 18 hingga 39 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT03150693Blinatumomab Consolidation in Real World
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07117136Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Menerima pesertaStudi observasional
Usia 0 hingga 38 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06131801CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Menerima pesertaFase 1/2
Usia 3 hingga 39 · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT05442515Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT03739814Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Menerima pesertaFase 1/2
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT03223610Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06144606Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Menerima pesertaFase 2
365 Days · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT07648264A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Menerima pesertaFase 3
Usia 1 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07223021Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Menerima pesertaFase 1/2
6 Months – 25 Years · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT06395103A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Menerima pesertaFase 1
Usia 0 hingga 18 · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT06173518UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
Menerima pesertaFase 1/2
31 Days – 30 Years · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT04544592Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT03666000A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Menerima pesertaFase 2
Usia 1 hingga 30 · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT04546399Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Menerima pesertaFase 1
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT05389423Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Menerima pesertaFase 3
365 Days – 25 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT03959085Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT06710418Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Menerima pesertaFase 2
Usia 7 hingga 25 · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT05082519AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Menerima pesertaFase 1/2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT06137118AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT06340737Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Agu 2026 · NCT06287229Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
Menerima pesertaFase 2
Usia 15 ke atas · Semua jenis kelamin · Diperbarui 10 Agu 2026 · NCT03136146Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Menerima pesertaFase 1/2
Usia 13 hingga 90 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT06533579Dari ClinicalTrials.gov, data diambil 3 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.